Adaptive Biotechnologies Corp (ADPT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.70B
Last updated: Nov 17, 2026 at 11:04 AM ET
Adaptive Biotechnologies Corp (ADPT) Financials: Revenue, Profit and Cash Flow
Adaptive Biotechnologies reported revenue of $276.98M for the fiscal year ended Dec 31, 2025, up 54.8% from the year before. That year, net income was -$59.46M with a net margin of -21.5%, operating cash flow was -$45.99M and free cash flow was -$48.95M. The quarter ended Sep 30, 2026 had revenue of $83.90M and net income of $2.81M.
Revenue and Margins
The operating margin was -20.6% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $15.69M, a compound annual rate of 43.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $276.98M | +54.8% | 74.2% | -20.6% | -21.5% |
| Dec 2024 | $178.96M | +5.1% | 59.7% | -90.8% | -89.2% |
| Dec 2023 | $170.28M | -8.1% | 55.6% | -133.3% | -132.3% |
| Dec 2022 | $185.31M | +20.1% | 68.7% | -108.0% | -108.1% |
| Dec 2021 | $154.34M | +56.9% | 68.1% | -135.4% | -134.3% |
| Dec 2020 | $98.38M | +15.6% | 77.1% | -155.3% | -148.6% |
| Dec 2019 | $85.07M | +52.8% | 73.8% | -92.1% | -80.6% |
| Dec 2018 | $55.66M | +254.8% | 64.7% | -89.4% | -83.4% |
| Dec 2017 | $15.69M | N/A | 0.1% | -283.5% | -273.0% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income fell 70.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M | $98.38M | $85.07M | $55.66M | $15.69M |
| Cost of revenue | $71.36M | $72.08M | $75.55M | $57.91M | $49.30M | $22.53M | $22.27M | $19.67M | $15.68M |
| Gross profit | $205.62M | $106.88M | $94.72M | $127.40M | $105.04M | $75.85M | $62.80M | $35.99M | $9.00K |
| Research and development | $93.77M | $102.95M | $122.12M | $141.76M | $142.34M | $116.07M | $70.70M | $39.16M | $32.00M |
| Operating income | -$57.12M | -$162.55M | -$227.03M | -$200.19M | -$208.97M | -$152.82M | -$78.39M | -$49.76M | -$44.48M |
| Net income | -$59.46M | -$159.59M | -$225.30M | -$200.37M | -$207.30M | -$146.23M | -$68.61M | -$46.45M | -$42.83M |
| EBITDA | -$41.80M | -$151.50M | -$213.99M | -$178.53M | -$187.78M | -$143.57M | -$75.06M | N/A | -$38.34M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.90M | $71.55M | $70.87M | $71.68M | $93.97M | $58.88M | $52.44M | $47.46M | $46.44M | $43.19M | $41.87M | $45.78M |
| Gross profit | $63.97M | $51.39M | $52.17M | $53.46M | $75.82M | $40.88M | $35.46M | $29.41M | $29.77M | $23.87M | $23.82M | $26.17M |
| Operating income | -$457.00K | -$15.77M | -$19.21M | -$12.77M | $10.29M | -$25.04M | -$29.60M | -$33.84M | -$32.63M | -$47.32M | -$48.76M | -$71.07M |
| Net income | $2.81M | -$39.94M | -$20.02M | -$13.58M | $9.54M | -$25.59M | -$29.83M | -$33.72M | -$32.10M | -$46.25M | -$47.53M | -$69.47M |
Balance Sheet
As of Dec 2025, total debt of $131.21M exceeded cash and equivalents by $60.71M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $512.74M | $539.38M | $661.13M | $856.62M | $923.34M | $1.12B | $912.30M | $332.69M | $362.49M |
| Current assets | $300.19M | $283.75M | $410.19M | $562.15M | $402.75M | $726.91M | $612.69M | $180.72M | $205.25M |
| Cash and equivalents | $70.50M | $47.92M | $65.06M | $90.03M | $139.06M | $123.44M | $96.58M | $55.03M | $85.31M |
| Total liabilities | $287.74M | $336.89M | $352.86M | $392.52M | $319.24M | $373.15M | $341.26M | $29.94M | $587.11M |
| Short-term debt | $4.64M | $865.00K | $0 | $9.23M | $5.05M | $3.53M | N/A | $0 | $0 |
| Long-term debt | $126.57M | $132.41M | $130.66M | $125.36M | N/A | N/A | N/A | $336.00K | $342.00K |
| Shareholder equity | $218.79M | $202.71M | $308.40M | $464.17M | $603.99M | $743.27M | $571.04M | -$258.11M | -$224.62M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $683.12M | $640.68M | $505.94M | $512.74M | $490.61M | $496.64M | $510.85M | $539.38M | $558.51M | $584.87M | $620.32M | $661.13M |
| Total liabilities | $499.23M | $490.02M | $281.70M | $287.74M | $286.36M | $317.10M | $320.63M | $336.89M | $334.93M | $343.44M | $345.56M | $352.86M |
| Cash and equivalents | $75.61M | $169.87M | $77.58M | $70.50M | $55.03M | $43.16M | $50.65M | $47.92M | $38.08M | $59.82M | $71.23M | $65.06M |
| Shareholder equity | $176.21M | $142.91M | $216.34M | $218.79M | $204.44M | $179.72M | $190.42M | $202.71M | $223.77M | $241.60M | $274.91M | $308.40M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.99M | -$95.21M | -$156.32M | -$183.94M | -$192.73M | -$149.68M | $205.40M | -$32.26M | -$34.86M |
| Capital expenditures | $2.96M | $3.66M | $10.70M | $16.35M | $61.75M | $18.80M | $11.20M | $6.30M | $2.42M |
| Free cash flow | -$48.95M | -$98.88M | -$167.02M | -$200.29M | -$254.47M | -$168.49M | $194.20M | -$38.56M | -$37.28M |
| Share repurchases | N/A | N/A | N/A | $0 | $0 | $321.00K | $4.99M | $0 | $0 |
| Investing cash flow | $37.95M | $77.79M | $129.65M | $2.90M | $181.21M | -$117.04M | -$481.70M | $736.00K | $36.43M |
| Financing cash flow | $30.40M | $241.00K | $2.25M | $132.26M | $27.15M | $293.59M | $319.92M | $1.25M | $50.03M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.61M | -$6.40M | -$9.54M | $2.06M | -$7.13M | -$12.43M | -$28.48M | -$12.49M | -$27.07M | -$17.30M | -$38.35M | -$26.93M |
| Capital expenditures | $1.93M | $1.18M | $796.00K | $636.00K | $409.00K | $655.00K | $1.26M | $80.00K | $344.00K | $1.73M | $1.51M | $1.30M |
| Free cash flow | $7.68M | -$7.58M | -$10.33M | $1.42M | -$7.54M | -$13.09M | -$29.74M | -$12.57M | -$27.41M | -$19.03M | -$39.86M | -$28.23M |
Frequently Asked Questions About ADPT
What is Adaptive Biotechnologies' annual revenue?
Adaptive Biotechnologies reported revenue of $276.98M for the fiscal year ended Dec 31, 2025.
How fast is Adaptive Biotechnologies' revenue growing?
Revenue was up 54.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.3%.
Is Adaptive Biotechnologies profitable?
No. Adaptive Biotechnologies reported net income of -$59.46M for the fiscal year ended Dec 31, 2025, with a net margin of -21.5%.
How much free cash flow does ADPT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$45.99M minus capital expenditures of $2.96M produced free cash flow of -$48.95M.
How much debt does Adaptive Biotechnologies have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $126.57M, short-term debt of $4.64M and cash and equivalents of $70.50M.
ADPT pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts